NLRP3 activators disrupt the endocytic AP2 complex and plasma membrane signaling

Stefan Ebner(University of Bonn), Felix Meissner(University of Bonn), Mikhail M. Savitski(European Molecular Biology Laboratory), Andreas U. Lindner(University of Bonn), Rainer Stahl(University of Bonn), Marta Lovotti(Innate Pharma (France)), Oliver J. Gerken(Biotechnology Institute Thurgau), Sebastian Kallabis(University of Bonn), Niels Schneberger(University of Bonn), Maria C. Tanzer(The University of Melbourne), Evi Kostenis(University of Bonn), Kshiti Meera Phulphagar(Broad Institute), Anushka Kudaliyanage(University of Bonn), Annika Frauenstein(University of Bonn), Isabelle Becher, Gregor Hagelueken(University of Bonn), Fabian Frechen(University of Bonn), Eva Kiermaier(University of Bonn), Anil Akbal(Innate Pharma (France)), Jonathan Jantsch(University of Cologne), Daniel F. Legler(Kogi State University), Dagmar Wachten(University of Bonn), Daniel N. Itzhak(Chan Zuckerberg Initiative (United States)), Benedikt Gansen(University of Bonn), Jessika Rollheiser(University of Bonn), David W. Will(European Molecular Biology Organization), Diana Fink(University of Bonn), Yubell Alvarez(University of Bonn), Tabea Klein(University of Bonn), Eicke Latz(German Rheumatism Research Centre), Lea Nguyen(University of Bonn), Jonas Walter(University of Bonn), Matthias Mann(Max Planck Institute of Biochemistry), Matthew S. J. Mangan(Innate Pharma (France)), Jonathan J. Swietlik(Max Planck Institute of Biochemistry), Georg H. H. Borner(Max Planck Institute of Biochemistry), Fraser Duthie(Innate Pharma (France))
bioRxiv (Cold Spring Harbor Laboratory)
February 25, 2026
Cited by 0


Related Papers